MDX2004
Advanced Cancers
Phase 1Active
Key Facts
About Opko Health
OPKO Health is a diversified, publicly-traded healthcare company with a three-pillar strategy encompassing commercial-stage therapeutics, a large-scale diagnostics business, and a research pipeline focused on multispecific therapies. Its key commercial asset is NGENLA™, a long-acting growth hormone therapy partnered with Pfizer and approved in over 40 markets. The company leverages partnerships with major pharmaceutical firms like Merck, Pfizer, and Regeneron to advance its pipeline while generating significant revenue from its diagnostic services, positioning it uniquely as an integrated player in the healthcare sector.
View full company profileTherapeutic Areas
Other Advanced Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| DC-6001 (DCBY02) | DynamiCure | Phase 1 |
| DC-6001 (DCSZ11) | DynamiCure | Phase 1 (Planned) |
| INA03 | Inatherys | Preclinical |
| IBI-110 | Innovent Biologics | Phase 2 |
| NXP900 | Nuvectis Pharma | Phase 1 |